Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L30 (RPL30)
- Target
- RPL30
- Molecular classification
- Ribosomal protein, Structural constituent of ribosome, Other (L30E family of ribosomal proteins)
01
Overview
60S ribosomal protein L30 (RPL30) is a structural protein component of the large 60S subunit of the eukaryotic ribosome. RPL30 is classified in the L30E family and is located in the cytoplasm[1][2][5]. It forms essential structural and functional contacts with ribosomal RNA and other ribosomal proteins to support protein synthesis. In addition to its canonical role, RPL30 is involved in ribosome biogenesis and, in mammals, participates in selenocysteine incorporation. Knockdown of RPL30 can disrupt ribosome assembly and indirectly lead to p53 stabilization and cell cycle arrest via nucleolar stress pathways[1]. There are no drugs that target RPL30, and it does not serve as a clinical biomarker or direct therapeutic target.
- Other names
- Large ribosomal subunit protein eL30RPL30L30eL3060S ribosomal protein L30
02
Mechanism of action
Not applicable
03
Biological functions
Structural role in the 60S ribosomal subunitProtein synthesis (translation)Ribosome biogenesismRNA binding (including selenocysteine insertion sequence binding)Regulation of p53 via nucleolar stress response (indirect)Autoregulates its own expression in yeast
04
Disease associations
Other (Not a direct driver of major disease categories, but ribosomal dysfunction can contribute to diseases such as ribosomopathies or indirectly influence cancer via the p53 pathway)No direct, specific disease association for RPL30 found in the results
05
Safety considerations
None specific
06
Interacting drugs
None known
07
Biomarkers
None established
Beyond the preview
Go deeper on 60S ribosomal protein L30 (RPL30).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 60S ribosomal protein L30 (RPL30).